Disease · HP_0000155
Oral ulcer
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Oral ulcer. Diseases, record HP_0000155. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0000155
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Oral ulcer
- Open Targets ID
- HP_0000155
- Other names
- Mouth ulcer, Oral mucosal ulceration
- Highest stage of its drugs
- Approval, for 3 of its 29 drugs, from DailyMed and EMA Human Drugs
Source Open Targets
Drugs29
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| APREMILAST | CHEMBL514800 | Small molecule | Approval | DailyMed and EMA Human Drugs | 5 | 3 | 3 | Drugs and targets |
| MENTHOL | CHEMBL256087 | Small molecule | Approval | DailyMed | 3 | 0 | 0 | Drugs and targets |
| DEXTROMETHORPHAN HYDROBROMIDE | CHEMBL1256818 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| MESALAMINE | CHEMBL704 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NEOMYCIN SULFATE | CHEMBL3989769 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| PROCAINE HYDROCHLORIDE | CHEMBL1200841 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| COLCHICINE | CHEMBL107 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| DOCONEXENT | CHEMBL367149 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
| FISH OIL | CHEMBL3833369 | Phase 2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets | |
| FISH OIL TRIGLYCERIDES | CHEMBL4297535 | Phase 2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
1 to 10 of 29
See all 29 drugsTargets72
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| NR3C1 | Glucocorticoid receptor | 3 | Glucocorticoid receptor agonist | Phase 1/2 | https://conductscience.org/library/genes/2908 | Drugs and targets |
| IFNAR1 | Interferon alpha/beta receptor | 2 | Interferon alpha/beta receptor agonist | Phase 2 | https://conductscience.org/library/genes/3454 | Drugs and targets |
| IFNAR2 | Interferon alpha/beta receptor | 2 | Interferon alpha/beta receptor agonist | Phase 2 | https://conductscience.org/library/genes/3455 | Drugs and targets |
| PDE4A | 3',5'-cyclic phosphodiesterase | 2 | 3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 4 inhibitor | Approval | https://conductscience.org/library/genes/5141 | Drugs and targets |
| PDE4B | 3',5'-cyclic phosphodiesterase | 2 | 3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 4 inhibitor | Approval | https://conductscience.org/library/genes/5142 | Drugs and targets |
| PDE4C | 3',5'-cyclic phosphodiesterase | 2 | 3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 4 inhibitor | Approval | https://conductscience.org/library/genes/5143 | Drugs and targets |
| PDE4D | 3',5'-cyclic phosphodiesterase | 2 | 3',5'-cyclic phosphodiesterase inhibitor; Phosphodiesterase 4 inhibitor | Approval | https://conductscience.org/library/genes/5144 | Drugs and targets |
| ADORA2A | Adenosine A2 receptor | 1 | Adenosine A2 receptor antagonist | Phase 2 | https://conductscience.org/library/genes/135 | Drugs and targets |
| ADORA2B | Adenosine A2 receptor | 1 | Adenosine A2 receptor antagonist | Phase 2 | https://conductscience.org/library/genes/136 | Drugs and targets |
| ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | 1 | Arachidonate 5-lipoxygenase inhibitor | Phase 3 | https://conductscience.org/library/genes/240 | Drugs and targets |
1 to 10 of 72
See all 72 targetsTrials16
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02307513 | A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease | Phase 3 | 207 | 2019-09-11 | Behçet's Syndrome | APREMILAST | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT03241030 | Sucralfate to Improve Oral Intake in Children With Infectious Oral Ulcers: a Randomized, Double-blind, Placebo-Controlled Trial | Phase 2 | 102 | 2021-10-29 | Herpangina, Gingivostomatitis, Hand, Foot and Mouth Disease | SUCRALFATE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT03878771 | PRF in Management of Chronic Multiple Oral Ulcers | Phase 1 | 804 | Oral Ulcer Due to Pemphius Vularis, Oral Ulcer Due to Benign Mucous Membrane Pemphioid, Oral Ulcer Due to Steven Johnson's Syndrome | CLOBETASOL PROPIONATE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT00857688 | Efficacy of the Combination Bismuth + Neomycin + Procaine in the Treatment of Recurrent Aphthous Ulceration | Phase 3 | 100 | Aphtous Ulcers | NEOMYCIN SULFATE, PROCAINE HYDROCHLORIDE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT04609397 | A Study to Evaluate the Efficacy and Safety of Hemay005 in the Treatment of Behçet Disease | Phase 2 | 89 | Behçet Disease | MUFEMILAST | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT04989049 | Therapeutic Effect of Folic Acid in Healing of Oral Ulcers | Early phase 1 | 75 | Oral Ulcer | FOLIC ACID | Its record names the disease | ClinicalTrials.gov | |
| NCT04528082 | Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease | Phase 3 | 60 | Behçet Disease | APREMILAST | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT05767047 | A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis | Phase 3 | 48 | Behçet's Disease, Juvenile Psoriatic Arthritis | APREMILAST | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT06084624 | Evaluation of Topical Rebamipide Versus Topical Betamethasone for Treatment of Oral Aphthous Ulcers | Phase 2 | 46 | Oral Aphthous Ulcers | BETAMETHASONE, REBAMIPIDE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT05449548 | Lenalidomide in the Treatment of Mucosal Behçet's Syndrome | Not applicable | 42 | Oral Ulcer | LENALIDOMIDE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 16
See all 16 trialsComparisons in its trials5
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Experimental Group vs Placebo Group: Number of Participants That Require Admission | 1 of 49 | 2 of 51 | 100 | NCT03241030 | Trial comparisons |
| Experimental Group vs Placebo Group: Number of Participants With Unscheduled Visits | 4 of 49 | 6 of 51 | 100 | NCT03241030 | Trial comparisons |
| Experimental Group vs Placebo Group: Number of Participants That Require Intravenous Fluid Administration | 5 of 49 | 1 of 51 | 100 | NCT03241030 | Trial comparisons |
| Experimental Group vs Placebo Group: deaths from any cause | 0 of 49 | 0 of 51 | 100 | NCT03241030 | Trial comparisons |
| Experimental Group vs Placebo Group: serious adverse events | 0 of 49 | 0 of 51 | 100 | NCT03241030 | Trial comparisons |
Papers from its trials8
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0000155
GET https://conductscience.org/api/diseases/v1/HP_0000155/drugs?page=2